AztraZeneca and Pieris Pharmaceuticals collaborate on treatment for respiratory conditions

18 August 2017

Gowling WLG's life sciences team has been instrumental in assisting longstanding client AstraZeneca on its collaboration with Pieris Pharmaceuticals.

This new partnership will accelerate the development and commercialisation of a new inhale treatment for respiratory diseases. This key and innovative collaboration benefits not only the clients themselves, but enhances the development of a new type of treatment for these conditions and may have significant benefits for patients.

The Life Sciences team was led by partner Patrick Duxbury.

The agreement will see Pieris receive upfront and near-term milestone payments. The company also has the potential to receive development-dependent milestones and commercial payments for the products, as well as tiered royalties. 

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.

Related   Life Sciences